Bluesky Project
Reimagining Canada’s Approval and Reimbursement System for Innovative Medicines February 2022
All Resources
Our resource hub to discover reports, policy papers and other forms of informative content
Filter by
Canadian public insurance plans and delays in patient access to innovative medicines
Canadians relying on public insurance plans face significant delays accessing new medicines. This graph breaks down the sequential approval and listing process, and demonstrates how long it takes Canadians to access innovative medicines.
Cost Drivers: Analysis of Private Drug Plans in Canada 2021
The 2021 Cost Drivers report highlights the consistent annual cost growth in the Canadian private drug benefits market and outlines factors that contribute to price increases.
2016-2019 Analysis of Private Drug Claim Cost Drivers
The 2016–2019 Cost Drivers report highlights annual cost growth in the Canadian private drug benefits market and outlines factors that contribute to price increases.
Explaining Public Reimbursement Delays for New Medicines for Canadian Patients
Canada and other OECD20 countries launch a similar number of innovative medicines. However, our public plans reimburse 32 to 45 per cent less.
Time to Listing: Canada’s public plans cover fewer new medicines and take longer than most OECD countries to approve them
Public plans in Canada cover fewer medicines than in other OECD20 countries and take longer to be approved. For rare-disease medicines, this gap is even larger.
